MARKET

MIRM

MIRM

Mirum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.17
-0.19
-0.78%
After Hours: 24.16 -0.01 -0.04% 16:28 08/14 EDT
OPEN
24.08
PREV CLOSE
24.36
HIGH
24.40
LOW
23.33
VOLUME
40.67K
TURNOVER
--
52 WEEK HIGH
28.31
52 WEEK LOW
6.51
MARKET CAP
613.90M
P/E (TTM)
-8.3793
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MIRM stock price target is 46.71 with a high estimate of 77.00 and a low estimate of 27.00.

EPS

MIRM News

More
Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
Business Wire · 08/07 20:05
Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates
Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates
Business Wire · 08/06 20:05
Mirum Pharmaceuticals files for $300M mixed shelf
Mirum Pharmaceuticals (MIRM +5.8%) has filed a prospectus for a $300M mixed shelf offering.
seekingalpha · 08/03 19:38
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 07/10 21:00
Heavy upside, catalysts ahead in liver disease space for Needham
Seeking Alpha - Article · 06/30 21:52
Baird finds heavy upside in treating pediatric liver diseases
Seeking Alpha - Article · 06/25 23:05
Baird Initiates Coverage On Mirum Pharmaceuticals with Outperform Rating, Announces Price Target of $30
Baird analyst Brian Skorney initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform rating and announces Price Target of $30.
Benzinga · 06/25 09:18
Baird Initiates Coverage Of Mirum Pharmaceuticals With Outperform, Price Target Of $30
Benzinga · 06/24 20:19

Industry

Biotechnology & Medical Research
-0.56%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The Company initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. It has commenced enrollment in the Phase III clinical trial in PFIC and also planning to initiate a Phase III clinical trial in ALGS. The Company is developing volixibat for the treatment of adult patients with cholestatic liver diseases and expect to initiate Phase II clinical trials. In addition to data from ongoing clinical trials of maralixibat.
More

Webull offers kinds of Mirum Pharmaceuticals Inc stock information, including NASDAQ:MIRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MIRM stock methods without spending real money on the virtual paper trading platform.